Image

GLS in Difficult CPB Weaning

GLS in Difficult CPB Weaning

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to learn whether global longitudinal strain (GLS), measured by echocardiography, can predict difficulty separating from cardiopulmonary bypass (CPB) in adults undergoing elective cardiac surgery.

The main questions it aims to answer are:

  • Can preoperative GLS measurement predict difficult separation from CPB?
  • Are GLS values associated with outcomes such as intensive care unit (ICU) stay, hospital stay, cardiac biomarkers, or 30-day mortality?

Participants will:

  • Undergo standard cardiac surgery requiring CPB
  • Have echocardiographic assessments (TTE before and after surgery)
  • Have their recovery and outcomes monitored, including ICU and hospital stay, postoperative labs, and survival within 30 days

Description

Background and Rationale

Difficult separation from cardiopulmonary bypass (CPB) is a serious intraoperative complication associated with increased perioperative morbidity and mortality. Myocardial contractility is the key determinant of successful CPB separation, and perioperative echocardiography is an established method for evaluating ventricular function. Conventionally, left ventricular ejection fraction (LVEF) measured by Simpson's biplane method is used to assess myocardial performance. However, LVEF has notable limitations, including high inter-operator variability, preload/afterload dependence, and poor sensitivity in detecting early myocardial dysfunction.

Global longitudinal strain (GLS), measured by two-dimensional speckle-tracking echocardiography, has emerged as a sensitive, reproducible, and geometry-independent parameter of myocardial function. GLS can detect subtle ventricular dysfunction earlier than conventional LVEF and has demonstrated prognostic value in a variety of clinical settings. Despite this, its use in the perioperative cardiac surgery population remains limited, partly due to uncertainty about the optimal timing of assessment. Anesthesia induction, CPB, and myocardial protection strategies may alter myocardial performance, and therefore both absolute GLS values and dynamic perioperative changes may carry prognostic significance.

Study Objectives

The primary objective of this prospective, multicenter, observational study is to evaluate the predictive value of GLS measurements for difficult separation from CPB. Specifically, the study will assess whether GLS measured by preoperative transthoracic echocardiography (TTE) can independently predict the need for multiple inotropic/vasoactive agents during CPB weaning.

Secondary objectives include exploring the associations between GLS parameters and postoperative outcomes such as intensive care unit (ICU) and hospital length of stay, postoperative changes in cardiac biomarkers, and all-cause 30-day mortality.

Methods

Eligible patients are adults (\>18 years) scheduled for elective cardiac surgery requiring CPB, including isolated valve replacement or repair, coronary artery bypass grafting (CABG), combined procedures, and ascending aortic/arch surgery. Patients undergoing emergency or redo surgery, those with contraindications to TEE, or in critical preoperative states (mechanical circulatory support, inotrope dependence, atrial fibrillation, or mechanical ventilation) are excluded.

Echocardiographic assessments are performed at standardized time points: preoperative TTE (T1), intraoperative TEE after induction (T2, if performed), before CPB initiation (T3), immediately after CPB weaning (T4), and following sternal closure (T5). Intraoperative TEE is not mandated by the protocol but may be performed according to institutional practice or operator discretion. GLS analysis follows American Society of Echocardiography (ASE) guidelines, averaging strain from 18 myocardial segments.

Anesthetic and surgical protocols follow institutional standards, with cardioplegia delivered via Buckberg's or del Nido solutions. Clinical, intraoperative, and postoperative data-including operative times, need for pharmacologic support, and recovery variables-are collected systematically by trained staff.

Outcomes

  • Primary Endpoint: Ability of GLS value to predict difficult CPB separation, defined as the need for at least two vasoactive or inotropic agents.
  • Secondary Endpoints: Association of GLS with ICU/hospital length of stay, postoperative biomarker trends, hospital readmission, and all-cause mortality within 30 days.

Significance

This study addresses a clinically important knowledge gap by evaluating the GLS as a novel predictor of intraoperative difficulty and adverse outcomes in cardiac surgery. If validated, GLS assessment could enhance perioperative risk stratification, guide intraoperative decision-making, and ultimately improve patient outcomes.

Eligibility

Inclusion Criteria

  • Age \> 18 years.
  • Scheduled for elective cardiac surgery requiring cardiopulmonary bypass (CPB).
  • Provided written informed consent to participate.
  • Eligible surgical procedures include:
    • Isolated mitral valve replacement or repair.
    • Isolated aortic valve replacement or repair.
    • Isolated coronary artery bypass grafting (CABG).
    • Combined valve and CABG surgery.
    • Multiple valve replacement or repair.
    • Surgery involving the ascending aorta or aortic arch.

Exclusion Criteria

  • Emergency cardiac surgery.
  • Redo cardiac surgery.
  • Contraindications to transesophageal echocardiography (TEE).
  • Critical preoperative conditions, including:
    • Ongoing inotropic drug therapy.
    • Preoperative mechanical circulatory support (e.g., IABP, ECMO, VAD).
    • Requirement for mechanical ventilation.
    • Preoperative atrial fibrillation.

Study details
    Cardiopulmonary Bypass
    Coronary Artery Bypass
    Heart Valve Diseases
    Echocardiography
    Intraoperative Complications
    Postoperative Complications (Cardiopulmonary)

NCT07390903

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

26 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.